12.20Open12.20Pre Close0 Volume1 Open Interest115.00Strike Price0.00Turnover332.77%IV59.49%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry12.20Extrinsic Value100Contract SizeAmericanOptions Type-0.0853Delta0.0007Gamma20.80Leverage Ratio-0.7205Theta-0.0192Rho-1.77Eff Leverage0.0989Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet